Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOLIRIS vs BENLYSTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.
Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.
Paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis,Atypical hemolytic uremic syndrome (a HUS) to inhibit complement-mediated thrombotic microangiopathy,Generalized myasthenia gravis (g MG) in adult patients who are anti-acetylcholine receptor antibody-positive,Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 antibody-positive
Systemic lupus erythematosus (SLE) in patients with active, autoantibody-positive disease receiving standard therapy,Lupus nephritis (in combination with standard therapy)
600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (a HUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).
Terminal elimination half-life: approximately 11.3 ± 3.4 days (range 8–18 days) following biweekly dosing. This supports a dosing interval of every 2 weeks for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
Eculizumab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved.
Belimumab is a monoclonal antibody and is not metabolized by cytochrome P450 enzymes; clearance is thought to occur via proteolytic degradation.
Eculizumab is not metabolized by cytochrome P450 enzymes; it is degraded via general protein catabolism. Clearance is primarily through the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). No biliary or fecal excretion data are available in humans.
Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
Eculizumab is a recombinant humanized monoclonal antibody; it does not bind to serum proteins significantly. Protein binding is negligible (approximately 0%), as it is a large protein molecule.
Approximately 65–70% bound to plasma proteins, primarily immunoglobulins and albumin.
Volume of distribution at steady state: approximately 7.5 L (0.11 L/kg in a 70 kg adult), indicating distribution primarily within the vascular and interstitial spaces, consistent with limited extravascular distribution of a large monoclonal antibody.
Vd ~ 0.19 L/kg (approximately 13.5 L for a 70 kg adult), indicating limited distribution primarily to the vascular space.
Intravenous administration only; bioavailability is 100% by the intravenous route. No oral or other routes are available.
SC: ~82% relative to IV; IV: 100%.
No dose adjustment required based on GFR. Eculizumab is not renally cleared.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD. Use caution and consider benefit-risk.
No specific guidelines for hepatic impairment; likely no adjustment needed as metabolism is not hepatic.
No dedicated studies; however, belimumab is not metabolized by the liver. No dose adjustment recommended based on Child-Pugh class.
For a HUS: weight-based: 5 to <10 kg: 300 mg; 10 to <20 kg: 600 mg; 20 to <30 kg: 600 mg; 30 to <40 kg: 900 mg; >=40 kg: 900 mg. Induction: weekly x4, then dose 1 week later, then maintenance every 2 weeks. For PNH: not approved in children <18 years.
In pediatric patients (>=5 years): IV: 10 mg/kg IV at 2-week intervals for first 3 doses, then 10 mg/kg IV every 4 weeks. SC: 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses). Not approved for children <5 years.
No specific dose adjustment. Monitor for infections, especially meningococcal, as elderly may have increased susceptibility.
No specific dose adjustment; select with caution due to greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or drug therapy. Monitor for infections and adverse reactions.
SOLIRIS increases the risk of meningococcal infections. Patients must receive meningococcal vaccination at least 2 weeks prior to administration, unless the risks of delaying therapy outweigh the risks of developing a meningococcal infection. Patients should be monitored for early signs of meningococcal infection and evaluated immediately if infection is suspected.
No FDA black box warning.
Increased susceptibility to meningococcal infections due to complement inhibition; vaccinate and monitor,Other Neisseria species and encapsulated bacteria infections (e.g., Streptococcus pneumoniae, Haemophilus influenzae type b); consider vaccination,Infusion reactions: including anaphylaxis and hypersensitivity; discontinue if severe,Monitoring for hemolysis in PNH patients: discontinue if evidence of severe hemolysis,Monitoring for thrombotic microangiopathy (TMA) in a HUS patients: discontinue if TMA complications occur
Hypersensitivity reactions including anaphylaxis,Infusion reactions,Increased risk of serious infections, including tuberculosis and opportunistic infections,Malignancy risk (potential),Hypogammaglobulinemia,Depression and suicidality
Unresolved serious Neisseria meningitidis infection,Patients not currently vaccinated against Neisseria meningitidis (unless delays in therapy outweigh risks),Known hypersensitivity to eculizumab or any of its excipients
None known; caution in patients with severe active infections.
No clinically significant food interactions reported; administer intravenously over 35 minutes.
No known food interactions. May be taken without regard to meals.
First trimester: No adequate human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Both mother and fetus may have increased risk of infections due to complement inhibition; monitor for meningococcal and other infections. No known structural teratogenicity.
First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell depletion as Ig G crosses placenta after 13 weeks gestation. Third trimester: Ig G actively transported across placenta; risk of neonatal immunosuppression (e.g., prolonged B-cell depletion, increased infection risk).
No human data; eculizumab is a large monoclonal antibody likely to be present in minimal amounts in breast milk due to molecular size; M/P ratio unknown. Caution advised.
No human data on belimumab in breast milk. Belimumab is a large monoclonal antibody likely present in milk at low concentrations. M/P ratio unknown. Developmental benefits of breastfeeding should be weighed against potential infant exposure and risk of immunosuppression.
No formal studies; pharmacokinetics may be altered due to increased plasma volume and renal function; consider monitoring drug levels if available, but no specific dose adjustment recommended.
No dose adjustment recommended based on pregnancy pharmacokinetic changes. However, caution advised due to limited data. Dose may need adjustment if concomitant immunosuppressants used.
Administer meningococcal vaccines at least 2 weeks prior to first dose; vaccinate against Neisseria meningitidis serogroups A, C, Y, W-135 and serogroup B. Monitor for hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) after discontinuation. Do not administer live vaccines. Infusion reactions may occur; premedicate with antihistamines and corticosteroids if needed. Eculizumab increases risk of serious infections, especially encapsulated bacteria. Prescribe prophylactic antibiotics if vaccination cannot be given 2 weeks prior. Monitor LDH, hemoglobin, and reticulocyte count in PNH.
BENLYSTA (belimumab) is a BLy S-specific inhibitor for adjunctive therapy in active systemic lupus erythematosus (SLE). Monitor for hypersensitivity reactions during infusion. Do not administer with live vaccines. Contraindicated in severe active lupus nephritis or severe active CNS lupus. Renal function monitoring required due to potential for progressive multifocal leukoencephalopathy (PML) risk.
You must receive meningococcal vaccines at least 2 weeks before starting treatment.,This medication increases your risk of serious infections, especially meningitis.,Report any signs of infection such as fever, headache with stiff neck, or rash immediately.,Do not receive live vaccines while on this medication.,If you stop treatment, your healthcare provider will monitor you for red blood cell breakdown.,Promptly report any bruises, bleeding, or signs of injection site reaction.
Report any signs of allergic reaction during or after infusion immediately.,Avoid live vaccines during treatment and for at least 30 days after stopping.,Inform doctor of any new or worsening neurological symptoms.,Use effective contraception during therapy and for 4 months after last dose.,Do not stop or change dose without consulting your rheumatologist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOLIRIS vs BENLYSTA, answered by our medical review team.
SOLIRIS is a Monoclonal Antibody that works by Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.. BENLYSTA is a Monoclonal Antibody that works by Belimumab is a human Ig G1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLy S, also known as BAFF), inhibiting its activity. BLy S is a cytokine that promotes B-cell survival and differentiation. By binding BLy S, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOLIRIS and BENLYSTA depend on the specific clinical indication. These are both Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOLIRIS is: 600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (a HUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.. The standard adult dose of BENLYSTA is: 10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOLIRIS and BENLYSTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOLIRIS is classified as Category C. First trimester: No adequate human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Both mother and fetus may have increased risk of infections. BENLYSTA is classified as Category C. First trimester: Based on animal studies, belimumab may cause fetal harm due to known immunomodulatory effects; limited human data. Second trimester: Potential for fetal B-cell dep. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.